Insider Transactions in Q4 2020 at Regeneron Pharmaceuticals, Inc. (REGN)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2020
|
George Yancopoulos Bd. Co-Chair, President & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
216,810
-12.16%
|
$104,719,230
$483.25 P/Share
|
|
Dec 30
2020
|
George Yancopoulos Bd. Co-Chair, President & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
398,079
+18.12%
|
$20,700,108
$52.03 P/Share
|
|
Dec 09
2020
|
Joseph J Larosa EVP General Counsel and Secret |
BUY
Grant, award, or other acquisition
|
Direct |
1,930
+10.55%
|
-
|
|
Dec 09
2020
|
Robert E Landry EVP Finance CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,930
+6.93%
|
-
|
|
Dec 09
2020
|
Christopher R. Fenimore SVP Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,719
+6.21%
|
-
|
|
Dec 09
2020
|
Neil Stahl EVP Research and Development |
BUY
Grant, award, or other acquisition
|
Direct |
1,688
+6.39%
|
-
|
|
Dec 09
2020
|
Marion Mc Court EVP Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
3,075
+8.59%
|
-
|
|
Dec 09
2020
|
Daniel P Van Plew EVP & General Mgr, Industrial |
BUY
Grant, award, or other acquisition
|
Direct |
6,930
+11.87%
|
-
|
|
Dec 09
2020
|
P Roy Vagelos Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,439
+1.02%
|
-
|
|
Dec 09
2020
|
Andrew J Murphy EVP Research |
BUY
Grant, award, or other acquisition
|
Direct |
10,214
+8.13%
|
-
|
|
Dec 01
2020
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.04%
|
$51,900
$520.0 P/Share
|
|
Nov 19
2020
|
P Roy Vagelos Director |
BUY
Bona fide gift
|
Indirect |
2,406
+40.0%
|
-
|
|
Nov 19
2020
|
P Roy Vagelos Director |
SELL
Bona fide gift
|
Indirect |
2,406
-4.79%
|
-
|
|
Nov 17
2020
|
Andrew J Murphy EVP Research |
SELL
Open market or private sale
|
Direct |
6,628
-0.69%
|
$3,612,260
$545.61 P/Share
|
|
Nov 16
2020
|
Andrew J Murphy EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
7,108
-11.68%
|
$3,987,588
$561.39 P/Share
|
|
Nov 16
2020
|
Andrew J Murphy EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
13,736
+18.41%
|
$412,080
$30.63 P/Share
|
|
Nov 13
2020
|
N Anthony Coles Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11
+1.65%
|
$3,795
$345.47 P/Share
|
|
Nov 02
2020
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.07%
|
$54,800
$548.92 P/Share
|
|
Oct 22
2020
|
Andrew J Murphy EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
5,185
+5.34%
|
$212,585
$41.33 P/Share
|
|
Oct 06
2020
|
P Roy Vagelos Director |
SELL
Bona fide gift
|
Indirect |
349
-0.24%
|
-
|
|
Oct 05
2020
|
Joseph L Goldstein Director |
SELL
Open market or private sale
|
Direct |
9,212
-62.01%
|
$5,527,200
$600.0 P/Share
|
|
Oct 05
2020
|
Joseph L Goldstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,212
+38.28%
|
$4,790,240
$520.01 P/Share
|
|
Oct 05
2020
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
1,000
-6.68%
|
$600,000
$600.0 P/Share
|
|
Oct 05
2020
|
Marion Mc Court EVP Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+6.26%
|
$342,000
$342.93 P/Share
|
|
Oct 01
2020
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.03%
|
$55,900
$559.51 P/Share
|